TLSI — TriSalus Life Sciences, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1826667 ·
Last close
$4.34
Market Cap
$267.23M
52W High
$7.95
52W Low
$2.20
ADV30
327,870
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 11,407,000 | 9,899,000 | -9,813,000 | -9,187,000 | 62,448,000 | 46,288,000 | 55,898,000 |
| Mar 2026 | 8,899,000 | 7,669,000 | -8,411,000 | 1,539,000 | 70,979,000 | 56,553,000 | 58,172,000 |
| Dec 2025 | 13,205,000 | 11,443,000 | -3,271,000 | -9,753,000 | 35,331,000 | 20,439,000 | 69,192,000 |
| Sep 2025 | 11,566,000 | 9,660,000 | -9,014,000 | -10,811,000 | 36,463,000 | 22,687,000 | 63,188,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,802,000
Investing CF
$-440,000
Financing CF
$42,690,000
CapEx
$-480,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.30
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-338,231,000
Inventory
$4,205,000
Receivables
$6,459,000
ST Investments
—
EBIT TTM
$-22,361,000
Pretax Income TTM
$-28,199,000
Interest Exp TTM
$5,838,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$45,077,000
EBITDA
$-29,949,000
Free Cash Flow
$-10,875,875
Enterprise Value
$275,383,520
Total Cash
$46,288,000
Total Debt
$34,426,000
Shares Out
61,574,600
Trailing EPS
$-1.33
Book Value
$0.11
ROE
—
ROA
-36.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 45,151,000 | -26,946,000 | -39,227,000 | 35,331,000 | 69,192,000 | -33,861,000 | -18,012,000 |
| Dec 2024 | 29,431,000 | -36,165,000 | -30,045,000 | 23,971,000 | 49,865,000 | -25,894,000 | -40,843,000 |
| Dec 2023 | 18,511,000 | -54,475,000 | -59,363,000 | 24,598,000 | 51,663,000 | -27,065,000 | -50,578,000 |
| Dec 2022 | 12,398,000 | -36,439,000 | -47,187,000 | 21,995,000 | 198,325,000 | -176,330,000 | -32,313,000 |
TTM Snapshot
Revenues TTM
$25,114,000
NetIncome TTM
$-11,514,000
OpCashFlow TTM
$0
Assets (Latest)
$23,971,000
Forward EPS
$-0.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OSUR | ORASURE TECHNOLOGIES INC | $271.05M | $3.93 | — |
| ANIK | Anika Therapeutics, Inc. | $272.61M | $20.37 | — |
| INFU | InfuSystem Holdings, Inc | $253.15M | $12.71 | — |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $292.66M | $4.50 | — |
| MOBI | Mobia Medical, Inc. | $301.62M | $9.06 | — |
News headlines (Yahoo Finance, 1h cache)
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance
2026-09-23 12:51 · Yahoo
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
2026-09-22 20:15 · Yahoo
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
2026-08-31 20:05 · Yahoo
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ...
2026-08-07 05:07 · Yahoo
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
2026-06-10 12:00 · Yahoo
TriSalus Life Sciences Inc (TLSI) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
2026-05-13 05:01 · Yahoo
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 21:15 · Yahoo
TriSalus (TLSI) Initiates Patient Enrollment for PREDICTT Liver Tumor Clinical Trial
2026-05-10 04:01 · Yahoo
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference
2026-08-18 04:01 · Yahoo
TriSalus Life Sciences Q2 Earnings Call Highlights
2026-08-07 17:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.